BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225-232. [PMID: 19508169 DOI: 10.1086/599371] [Cited by in Crossref: 175] [Cited by in F6Publishing: 176] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;109:62-70. [PMID: 24112091 DOI: 10.1111/add.12367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
2 McKibben RA, Haberlen SA, Post WS, Brown TT, Budoff M, Witt MD, Kingsley LA, Palella FJ, Thio CL, Seaberg EC. A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study. J Infect Dis. 2016;213:257-265. [PMID: 26216904 DOI: 10.1093/infdis/jiv396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
3 Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165-S173. [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005] [Cited by in Crossref: 163] [Cited by in F6Publishing: 144] [Article Influence: 23.3] [Reference Citation Analysis]
4 Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010;7:69-76. [PMID: 20425560 DOI: 10.1007/s11904-010-0041-9] [Cited by in Crossref: 216] [Cited by in F6Publishing: 201] [Article Influence: 19.6] [Reference Citation Analysis]
5 Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, Tanaka J. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. J Viral Hepat 2021;28:1293-303. [PMID: 34185932 DOI: 10.1111/jvh.13562] [Reference Citation Analysis]
6 Marinho GB, Tenório JR, Munhoz L, Andrade NS, Arita ES, Ortega KL. Detection of calcified atheromas on panoramic radiographs of cirrhotic patients. Spec Care Dentist 2021;41:164-9. [PMID: 33258155 DOI: 10.1111/scd.12551] [Reference Citation Analysis]
7 Rzouq F, Olyaee M, Alahdab F. Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope. The American Journal of the Medical Sciences 2014;348:426-30. [DOI: 10.1097/maj.0000000000000291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res 2017;8:89-97. [PMID: 28149645 DOI: 10.1016/j.jare.2016.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wen D, Du X, Dong JZ, Ma CS. Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis. Eur J Intern Med 2019;63:69-73. [PMID: 31006509 DOI: 10.1016/j.ejim.2019.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol 2018;11:519-24. [PMID: 29498556 DOI: 10.1080/17512433.2018.1447923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553-561. [PMID: 28634198 DOI: 10.1136/gutjnl-2017-313983] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 16.5] [Reference Citation Analysis]
12 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063] [Reference Citation Analysis]
13 Jena AB, Snider JT, Diaz Espinosa O, Ingram A, Sanchez Gonzalez Y, Lakdawalla D. How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom? Value Health 2019;22:669-76. [PMID: 31198184 DOI: 10.1016/j.jval.2018.09.2923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
14 Tsai MC, Yang TW, Wang CC, Wang YT, Sung WW, Tseng MH, Lin CC. Favorable clinical outcome of nonalcoholic liver cirrhosis patients with coronary artery disease: A population-based study. World J Gastroenterol 2018;24:3547-55. [PMID: 30131661 DOI: 10.3748/wjg.v24.i31.3547] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Taylor BS, So-Armah K, Tate JP, Marconi VC, Koethe JR, Bedimo RJ, Butt AA, Gibert CL, Goetz MB, Rodriguez-Barradas MC, Womack JA, Gerschenson M, Lo Re V 3rd, Rimland D, Yin MT, Leaf D, Tracy RP, Justice AC, Freiberg MS. HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr 2017;75:500-8. [PMID: 28696344 DOI: 10.1097/QAI.0000000000001444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
16 Elsemman IE, Mardinoglu A, Shoaie S, Soliman TH, Nielsen J. Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism. Mol Biosyst. 2016;12:1496-1506. [PMID: 27040643 DOI: 10.1039/c5mb00827a] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Wang C, Kao J. Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box. Hepatology 2010;51:343-343. [DOI: 10.1002/hep.23393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ilyas SZ, Tabassum R, Hamed H, Rehman SU, Qadri I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunol 2017;30:633-41. [PMID: 28953449 DOI: 10.1089/vim.2017.0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Lan CW, Fiellin DA, Barry DT, Bryant KJ, Gordon AJ, Edelman EJ, Gaither JR, Maisto SA, Marshall BD. The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods. Am J Addict 2016;25:7-24. [PMID: 26693830 DOI: 10.1111/ajad.12319] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
20 Shitole SG, Lazar JM, Hanna DB, Kim RS, Anastos K, Garcia MJ, Tien PC, Lima JAC, Kaplan RC, Kizer JR. HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women. AIDS 2021;35:1647-55. [PMID: 33859109 DOI: 10.1097/QAD.0000000000002920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Salam RA, Nabil B, Saber M, AbdelWahab HA, Saber T. Prevalence of Hepatitis C Virus Seropositivity and Its Impact on Coronary Artery Disease among Egyptian Patients Referred for Coronary Angiography. Cardiol Res Pract 2016;2016:1623197. [PMID: 27882261 DOI: 10.1155/2016/1623197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Chkhartishvili N, Bolokadze N, Rukhadze N, Dvali N, Abutidze A, Sharvadze L, Tsertsvadze T. Impact of hepatitis C virus antibody positivity on mortality and causes of death in people living with HIV in Georgia. Int J STD AIDS 2019;30:1185-93. [PMID: 31558133 DOI: 10.1177/0956462419866055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, Neely RD. Hepatitis C virus and atherosclerosis: A legacy after virologic cure? Clin Res Hepatol Gastroenterol 2017;41:25-30. [PMID: 27840032 DOI: 10.1016/j.clinre.2016.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Chen JY, Ren Y, Yan P, Belina ME, Chung RT, Butt AA. Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES. J Viral Hepat 2018;25:825-33. [PMID: 29478294 DOI: 10.1111/jvh.12884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 Lucas GM, Atta MG, Fine DM, McFall AM, Estrella MM, Zook K, Stein JH. HIV, Cocaine Use, and Hepatitis C Virus: A Triad of Nontraditional Risk Factors for Subclinical Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2016;36:2100-7. [PMID: 27609369 DOI: 10.1161/ATVBAHA.116.307985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Polanka BM, Kundu S, So-Armah KA, Freiberg MS, Gupta SK, Bedimo RJ, Budoff MJ, Butt AA, Chang CH, Gottlieb SS, Marconi VC, Womack JA, Stewart JC. Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 2019;81:110-7. [PMID: 30768487 DOI: 10.1097/QAI.0000000000001981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Basseri B, Yamini D, Chee G, Enayati PDP, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection: Hepatitis C and comorbidities. Liver International 2010;30:1012-8. [DOI: 10.1111/j.1478-3231.2010.02235.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
28 May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr 2015;69:348-54. [PMID: 25848927 DOI: 10.1097/QAI.0000000000000603] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
29 Masia M, Robledano C, Lopez N, Escolano C, Gutierrez F. Treatment for hepatitis C virus with pegylated interferon-  plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. Journal of Antimicrobial Chemotherapy 2011;66:1861-8. [DOI: 10.1093/jac/dkr202] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
30 Chew KW, Liu CY, Ambale-Venkatesh B, Liao D, Horwich TB, Lima JAC, Bluemke DA, Paul Finn J, Butt AA, Currier JS. Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. J Int Med Res 2017;45:1693-707. [PMID: 28606026 DOI: 10.1177/0300060517708919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
31 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
32 Romano C, Cuomo G, Ferrara R, Del Mastro A, Esposito S, Sellitto A, Adinolfi LE. Uncommon immune-mediated extrahepatic manifestations of HCV infection. Expert Rev Clin Immunol. 2018;14:1089-1099. [PMID: 30338718 DOI: 10.1080/1744666x.2018.1538790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
33 Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, Butt AA; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study. Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. AIDS Res Hum Retroviruses 2015;31:718-22. [PMID: 25858663 DOI: 10.1089/AID.2014.0284] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
34 Lin MS, Guo SE, Lin HS, Hsu JT, Lin YS, Lin TH, Huang TJ, Chen MY, Chung CM. Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study. Obes Facts 2016;9:101-11. [PMID: 27054361 DOI: 10.1159/000443692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
35 Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS One. 2014;9:e106376. [PMID: 25184517 DOI: 10.1371/journal.pone.0106376] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
36 Gonzalez HC, Gordon SC. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gastroenterol Clin North Am 2020;49:301-14. [PMID: 32389364 DOI: 10.1016/j.gtc.2020.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Honda A, Matsuzaki Y. Cholesterol and chronic hepatitis C virus infection. Hepatol Res 2011;41:697-710. [PMID: 21682830 DOI: 10.1111/j.1872-034X.2011.00838.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
38 Cacoub P, Comarmond C. Considering hepatitis C virus infection as a systemic disease. Semin Dial 2019;32:99-107. [PMID: 30549107 DOI: 10.1111/sdi.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Benjamin LA, Bryer A, Lucas S, Stanley A, Allain TJ, Joekes E, Emsley H, Turnbull I, Downey C, Toh CH, Brown K, Brown D, Ison C, Smith C, Corbett EL, Nath A, Heyderman RS, Connor MD, Solomon T. Arterial ischemic stroke in HIV: Defining and classifying etiology for research studies. Neurol Neuroimmunol Neuroinflamm 2016;3:e254. [PMID: 27386505 DOI: 10.1212/NXI.0000000000000254] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 6.6] [Reference Citation Analysis]
40 Petta S, Craxì A. Extrahepatic Manifestations of Chronic Viral C Hepatitis. Gastroenterol Clin North Am 2020;49:347-60. [PMID: 32389367 DOI: 10.1016/j.gtc.2020.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Huang QT, Hang LL, Zhong M, Gao YF, Luo ML, Yu YH. Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies. Medicine (Baltimore) 2016;95:e4777. [PMID: 27583932 DOI: 10.1097/MD.0000000000004777] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
43 Mukhopadhyay A, Maulik U. Network-based study reveals potential infection pathways of hepatitis-C leading to various diseases. PLoS One 2014;9:e94029. [PMID: 24743187 DOI: 10.1371/journal.pone.0094029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
44 Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2013;:CD008944. [PMID: 24101439 DOI: 10.1002/14651858.CD008944.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
45 Kakinami L, Adams MJ, Block RC, Cohn SE, Maliakkal B, Fisher SG. Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients. AIDS Res Hum Retroviruses 2012;28:1552-6. [PMID: 22380598 DOI: 10.1089/AID.2011.0392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Forde KA, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V 3rd. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat. 2012;19:271-277. [PMID: 22404725 DOI: 10.1111/j.1365-2893.2011.01545.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
47 Freiberg MS, Chang CC, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Goetz MB, Butt AA, Rodriguez Barradas MC. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4:425-432. [PMID: 21712519 DOI: 10.1161/circoutcomes.110.957415] [Cited by in Crossref: 76] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
48 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
49 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
50 Ishizaka N, Ishizaka Y, Yamkado M. Atherosclerosis as a possible extrahepatic manifestation of chronic hepatitis C virus infection. Clin Med Insights Cardiol. 2014;8:1-5. [PMID: 25452704 DOI: 10.4137/cmc.s17069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
51 Butt AA, Yan P, Marks K, Shaikh OS, Sherman KE; ERCHIVES Study Team. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Aliment Pharmacol Ther 2016;44:728-37. [PMID: 27459341 DOI: 10.1111/apt.13748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
52 Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Dig Liver Dis. 2011;43:411-415. [PMID: 21310673 DOI: 10.1016/j.dld.2010.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
53 Voulgaris T, Sevastianos VA. Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus. Hepat Res Treat 2016;2016:7629318. [PMID: 26885388 DOI: 10.1155/2016/7629318] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
54 Piekarska A, Mamzer-Dachnowska A, Kasprzak JD, Peruga JZ, Kaszuba A, Berkan-Kawińska A. Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls - PRO-CARDIO-C study. Clin Exp Hepatol 2019;5:118-22. [PMID: 31501787 DOI: 10.5114/ceh.2019.84782] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 So-Armah KA, Lim JK, Lo Re V 3rd, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS; VACS Project Team. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Prog Cardiovasc Dis 2020;63:184-91. [PMID: 32068085 DOI: 10.1016/j.pcad.2020.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Butt AA, Ren Y, Lo Re V, Taddei TH, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin Infect Dis. 2017;65:64-72. [PMID: 28369305 DOI: 10.1093/cid/cix224] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
57 Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RDG. Lipids and HCV. Semin Immunopathol 2013;35:87-100. [DOI: 10.1007/s00281-012-0356-2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
58 Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Liver Int 2016;36:1275-83. [PMID: 26928927 DOI: 10.1111/liv.13103] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
59 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
60 Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:465-73. [PMID: 28689586 DOI: 10.1016/j.cld.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
61 Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther 2016;5:491-508. [PMID: 27783223 DOI: 10.1007/s40121-016-0134-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
62 Speliotes EK, Balakrishnan M, Friedman LS, Corey KE. Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol 2018;16:1189-96. [PMID: 29684459 DOI: 10.1016/j.cgh.2018.04.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
63 Kanellopoulou T, Alexopoulou A, Kontopidou FN, Konstantinides P, Papatheodoridis GV. The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. Ann Gastroenterol 2016;29:201-7. [PMID: 27065733 DOI: 10.20524/aog.2016.0013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Chew KW, Hua L, Bhattacharya D, Butt AA, Bornfleth L, Chung RT, Andersen JW, Currier JS. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2014;1:ofu104. [PMID: 25734172 DOI: 10.1093/ofid/ofu104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
65 Serres L, Vasseur P, Tougeron D, Gand E, Chagneau-Derrode C, Charier F, Rochd S, Silvain C. Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution. Eur J Gastroenterol Hepatol 2015;27:1286-92. [PMID: 26275081 DOI: 10.1097/MEG.0000000000000453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
66 Wheeler AL, Scherzer R, Lee D, Delaney JA, Bacchetti P, Shlipak MG, Sidney S, Grunfeld C, Tien PC; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection. AIDS 2014;28:49-58. [PMID: 24136113 DOI: 10.1097/QAD.0000000000000026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
67 Butt AA, Yan P, Shaikh OS, Freiberg MS, Lo Re V 3rd, Justice AC, Sherman KE; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015;22:691-700. [PMID: 25524834 DOI: 10.1111/jvh.12375] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
68 Nielsen NS, Jespersen S, Gaardbo JC, Arnbjerg CJ, Clausen MR, Kjær M, Gerstoft J, Ballegaard V, Ostrowski SR, Nielsen SD. Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection. Int J Mol Sci 2017;18:E1016. [PMID: 28481325 DOI: 10.3390/ijms18051016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
69 Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423. [PMID: 26660706 DOI: 10.1007/s12072-015-9684-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 12.8] [Reference Citation Analysis]
70 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
71 Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol. 2014;20:2825-2838. [PMID: 24659875 DOI: 10.3748/wjg.v20.i11.2825] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
72 Tarancon-Diez L, De Pablo-Bernal RS, Álvarez-Rios AI, Rosado-Sánchez I, Dominguez-Molina B, Genebat M, Pacheco YM, Jiménez JL, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. Thromb Haemost 2017;117:1141-9. [PMID: 28276569 DOI: 10.1160/TH16-11-0867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
73 Pendyal A, Gelow JM. Cardiohepatic Interactions. Heart Failure Clinics 2016;12:349-61. [DOI: 10.1016/j.hfc.2016.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
74 Guzmán-Fulgencio M, Berenguer J, de Castro IF, Micheloud D, López JC, Cosín J, Miralles P, Lorente R, Aldamiz-Echevarría T, Muñoz-Fernández MÁ, Resino S. Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. J Antimicrob Chemother 2011;66:645-9. [PMID: 21393232 DOI: 10.1093/jac/dkq518] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
75 Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin Exp Hepatol. 2015;1:17-29. [PMID: 28856251 DOI: 10.5114/ceh.2015.51375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 Chou CH, Ho CS, Tsai WC, Wang MC, Tsai YS, Chen JY. Effects of chronic hepatitis C infection on arterial stiffness. J Am Soc Hypertens. 2017;11:716-723. [PMID: 28923555 DOI: 10.1016/j.jash.2017.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
77 Wu VC, Chen TH, Wu M, Cheng CW, Chen SW, Chang CW, Chen CC, Chang SH, Hung KC, Chern MS, Lin FC, Chu PH, Wu CS. Comparison of cardiovascular outcomes and all-cause mortality in patients with chronic hepatitis B and C: A 13-year nationwide population-based study in Asia. Atherosclerosis 2018;269:178-84. [PMID: 29366991 DOI: 10.1016/j.atherosclerosis.2018.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
78 Chen YC, Chiou WY, Hung SK, Su YC, Hwang SJ. Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan. BMC Nephrol. 2013;14:187. [PMID: 24011024 DOI: 10.1186/1471-2369-14-187] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
79 Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468. [PMID: 20163481 DOI: 10.1111/j.1468-1293.2009.00815.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 50] [Article Influence: 1.1] [Reference Citation Analysis]
80 Bailey AL, Al-Adwan S, Sneij E, Campbell N, Wiisanen ME. Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection. Curr Cardiol Rep 2021;23:52. [PMID: 33822282 DOI: 10.1007/s11886-021-01475-6] [Reference Citation Analysis]
81 Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clin Infect Dis 2017;65:1542-50. [PMID: 29020184 DOI: 10.1093/cid/cix564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
82 Hodowanec AC, Lee RD, Brady KE, Gao W, Kincaid S, Plants J, Bahk M, Mackman N, Landay AL, Huhn GD. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis. 2015;15:190. [PMID: 25884329 DOI: 10.1186/s12879-015-0920-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
83 Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Madhivanan P, Maziak W. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis. J Viral Hepat. 2017;24:998-1004. [PMID: 28502092 DOI: 10.1111/jvh.12725] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
84 Caballero-Marcos A, Romero-Cristóbal M, Puerto M, Fernández-Yunquera A, Dieguez L, Navarrete C, Clemente A, Diaz-Fontenla F, Catalán P, Rincón D, López-Baena JÁ, Bañares Cañizares R, Salcedo M. HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation. Transpl Int 2021. [PMID: 34346111 DOI: 10.1111/tri.14000] [Reference Citation Analysis]
85 Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. Curr HIV/AIDS Rep 2019;16:389-94. [PMID: 31482299 DOI: 10.1007/s11904-019-00466-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
86 Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int 2013;7 Suppl 2:782-9. [PMID: 24587848 DOI: 10.1007/s12072-013-9460-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
87 Butt AA, Yan P, Shaikh OS, Lo Re V, Abou-samra A, Sherman KE. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. Journal of Hepatology 2020;73:277-84. [DOI: 10.1016/j.jhep.2020.02.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
88 Hoffmeister PA, Hingorani SR, Storer BE, Baker KS, Sanders JE. Hypertension in long-term survivors of pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010;16:515-24. [PMID: 19961945 DOI: 10.1016/j.bbmt.2009.11.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
89 Fabrizi F, Messa P, Martin P. The Unravelled Link between Chronic Kidney Disease and Hepatitis C Infection. New Journal of Science 2014;2014:1-9. [DOI: 10.1155/2014/180203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
90 Li Y, Iso H, Cui R, Murakami Y, Yatsuya H, Miura K, Nagasawa SY, Ueshima H, Okamura T; EPOCH-JAPAN Research Group. Serum γ-glutamyltransferase and Mortality due to Cardiovascular Disease in Japanese Men and Women. J Atheroscler Thromb 2016;23:792-9. [PMID: 26875518 DOI: 10.5551/jat.32698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
91 Mohammed AQ, Auckle R, Li HL, Xu SL, Liu L, Zhao DD, Che WL. Pegylated Interferon-α Plus Ribavirin Therapy Improves Left Ventricular Diastolic Dysfunction in Patients With Chronic Hepatitis C Attaining Sustained Virological Response. Am J Med Sci 2018;355:566-72. [PMID: 29891040 DOI: 10.1016/j.amjms.2018.02.001] [Reference Citation Analysis]
92 Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013;5:528-40. [PMID: 24179612 DOI: 10.4254/wjh.v5.i10.528] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 17.1] [Reference Citation Analysis]
93 Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Womens Health 2011;11:36. [PMID: 21816091 DOI: 10.1186/1472-6874-11-36] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
94 Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 2014;63:369-75. [DOI: 10.1136/gutjnl-2013-306102] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
95 Katsi V, Felekos I, Skevofilax S, Aggeli C, Tousoulis D, Stefanadis C, Kallikazaros I. Cardiovascular Disease and Hepatitis C Virus Infection: An Irrelevant Statement or a Hot Relationship? Cardiology in Review 2015;23:11-7. [DOI: 10.1097/crd.0000000000000031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
96 Lapumnuaypol K, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis. Hosp Pract (1995). 2019;47:105-110. [PMID: 31018721 DOI: 10.1080/21548331.2019.1612066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
97 Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, Lichtner M. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One 2017;12:e0179400. [PMID: 28636655 DOI: 10.1371/journal.pone.0179400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
98 Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, Freiberg MS. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis 2013;13:399. [PMID: 23987993 DOI: 10.1186/1471-2334-13-399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
99 Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24:469-482. [PMID: 25801890 DOI: 10.1177/0961203314556140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
100 Forde KA, Haynes K, Troxel AB, Trooskin S, Osterman MT, Kimmel SE, Lewis JD, Lo Re V. Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study. J Viral Hepat. 2012;19:271-277. [PMID: 22404725 DOI: 10.1111/j.1365-2893.2011.01545] [Reference Citation Analysis]
101 Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410-3417. [PMID: 24707124 DOI: 10.3748/wjg.v20.i13.3410] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 95] [Article Influence: 17.8] [Reference Citation Analysis]
102 Elhendawy M, Abo-Ali L, Abd-Elsalam S, Hagras MM, Kabbash I, Mansour L, Atia S, Esmat G, Abo-ElAzm AR, El-Kalla F, Kobtan A. HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. Environ Sci Pollut Res Int 2020;27:33659-67. [PMID: 32533486 DOI: 10.1007/s11356-020-09591-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
103 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36:621-627. [PMID: 26763484 DOI: 10.1111/liv.13064] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
104 Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE; ERCHIVES study. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int 2016;36:651-8. [PMID: 26616353 DOI: 10.1111/liv.13036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
105 Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-9. [PMID: 21338329 DOI: 10.1089/AID.2011.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
106 Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178-185. [PMID: 25485735 DOI: 10.1001/jamainternmed.2014.6502] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 9.5] [Reference Citation Analysis]
107 Chew KW, Bhattacharya D, Horwich TB, Yan P, McGinnis KA, Tseng C, Freiberg MS, Currier JS, Butt AA. Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons. J Viral Hepat 2017;24:814-22. [PMID: 28273386 DOI: 10.1111/jvh.12705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
108 Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol. 2015;21:8293-8303. [PMID: 26217081 DOI: 10.3748/wjg.v21.i27.8293] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
109 Butt AA, Yan P, Chew KW, Currier J, Corey K, Chung RT, Shuaib A, Abou-Samra AB, Butler J, Freiberg MS. Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clin Infect Dis 2017;65:557-65. [PMID: 28444148 DOI: 10.1093/cid/cix359] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
110 Perticone M, Miceli S, Maio R, Caroleo B, Sciacqua A, Tassone EJ, Greco L, Staltari O, Sesti G, Perticone F. Chronic HCV infection increases cardiac left ventricular mass index in normotensive patients. Journal of Hepatology 2014;61:755-60. [DOI: 10.1016/j.jhep.2014.05.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
111 Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther. 2014;31:891-903. [PMID: 25047758 DOI: 10.1007/s12325-014-0138-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
112 Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis 2012;55:631-8. [PMID: 22563020 DOI: 10.1093/cid/cis463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
113 Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging. 2012;32:421-430. [PMID: 23031062 DOI: 10.1111/j.1475-097x.2012.01152.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
114 Palaniswamy C, Aronow WS, Sukhija R, Chugh T, Ramdeen N, Kalapatapu K, Weiss MB, Pucillo AL, Monsen CE. Major adverse cardiac events in patients with hepatitis C infection treated with bare-metal versus drug-eluting stents. Clin Cardiol 2010;33:367-70. [PMID: 20556808 DOI: 10.1002/clc.20764] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
115 Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli MA, Bernstein D. Higher Prevalence and More Severe Coronary Artery Disease in Hepatitis C Virus-infected Patients: A Case Control Study. J Clin Exp Hepatol. 2013;3:186-191. [PMID: 25755499 DOI: 10.1016/j.jceh.2013.05.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
116 Pothineni NV, Delongchamp R, Vallurupalli S, Ding Z, Dai Y, Hagedorn CH, Mehta JL. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. Am J Cardiol. 2014;114:1841-1845. [PMID: 25438910 DOI: 10.1016/j.amjcard.2014.09.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
117 So-Armah K, Gupta SK, Kundu S, Stewart JC, Goulet JL, Butt AA, Sico JJ, Marconi VC, Crystal S, Rodriguez-Barradas MC, Budoff M, Gibert CL, Chang CC, Bedimo R, Freiberg MS. Depression and all-cause mortality risk in HIV-infected and HIV-uninfected US veterans: a cohort study. HIV Med 2019;20:317-29. [PMID: 30924577 DOI: 10.1111/hiv.12726] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
118 Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4-17. [PMID: 29653647 DOI: 10.1016/j.ahj.2017.10.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
119 Harada R, Kimura M, Sato Y, Taniguchi T, Tomonari T, Tanaka T, Tanaka H, Muguruma N, Shinomiya H, Honda H, Imoto I, Sogabe M, Okahisa T, Takayama T. APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism. BMC Gastroenterol 2018;18:24. [PMID: 29382324 DOI: 10.1186/s12876-018-0747-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
120 Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, Reichman T, Matherly SC, Driscoll C, Lee H, Luketic VA, Sterling RK, Sanyal AJ, Patel V, Levy M, Siddiqui MS. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl. 2018;24:333-342. [PMID: 29328556 DOI: 10.1002/lt.25012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 13.3] [Reference Citation Analysis]
121 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063-016-1454-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
122 Sciacqua A, Perticone M, Tassone EJ, Cimellaro A, Caroleo B, Miceli S, Andreucci M, Licata A, Sesti G, Perticone F. Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance. Intern Emerg Med 2016;11:553-9. [PMID: 26597876 DOI: 10.1007/s11739-015-1349-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Angelovich TA, Hearps AC, Jaworowski A. Inflammation-induced foam cell formation in chronic inflammatory disease. Immunol Cell Biol 2015;93:683-93. [PMID: 25753272 DOI: 10.1038/icb.2015.26] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
124 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched. World J Gastroenterol 2021;27:2771-83. [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
125 Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58:1055-1061. [PMID: 24523214 DOI: 10.1093/cid/ciu077] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 12.3] [Reference Citation Analysis]
126 Barone M, Viggiani MT, Amoruso A, Schiraldi S, Zito A, Devito F, Cortese F, Gesualdo M, Brunetti N, Di Leo A, Scicchitano P, Ciccone MM. Endothelial dysfunction correlates with liver fibrosis in chronic HCV infection. Gastroenterol Res Pract. 2015;2015:682174. [PMID: 26000012 DOI: 10.1155/2015/682174] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
127 Ambrosino P, Lupoli R, Di Minno A, Tarantino L, Spadarella G, Tarantino P, Nasto A, Celentano A, Di Minno MN. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. Int J Cardiol. 2016;221:746-754. [PMID: 27428315 DOI: 10.1016/j.ijcard.2016.06.337] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
128 Clement ME, Park LP, Navar AM, Okeke NL, Pencina MJ, Douglas PS, Naggie S. Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. Clin Infect Dis 2016;63:407-13. [PMID: 27143663 DOI: 10.1093/cid/ciw289] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
129 Shitole SG, Kuniholm MH, Hanna DB, Boucher T, Peng AY, Berardi C, Shah T, Bortnick AE, Christia P, Scheuer J, Kizer JR. Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community. Atherosclerosis 2020;311:60-6. [PMID: 32947199 DOI: 10.1016/j.atherosclerosis.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-50. [PMID: 19889081 DOI: 10.1111/j.1478-3231.2009.02156.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
131 Cacoub P. Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor. Gastroenterology 2019;156:862-4. [DOI: 10.1053/j.gastro.2019.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
132 Lin MS, Guo SE, Chen MY, Huang TJ, Huang JC, Hu JH, Lin YS. The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram. Am J Med Sci. 2014;347:478-484. [PMID: 24335568 DOI: 10.1097/maj.0b013e3182a5587d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
133 Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. Cells 2019;8:E252. [PMID: 30884773 DOI: 10.3390/cells8030252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
134 Jha HC. Impact of viral and bacterial infections in coronary artery disease patients. WJTM 2013;2:0. [DOI: 10.5528/wjtm.v2.i3.49] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
135 Adinolfi LE, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12:2215-2234. [PMID: 21883025 DOI: 10.1517/14656566.2011.597742] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
136 So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, Leaf D, Rimland D, Rodriguez-Barradas MC, Budoff MJ, Samet JH, Kuller LH, Deeks SG, Crothers K, Tracy RP, Crane HM, Sajadi MM, Tindle HA, Justice AC, Freiberg MS; VACS Project Team. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? J Acquir Immune Defic Syndr 2016;72:206-13. [PMID: 27824677 DOI: 10.1097/QAI.0000000000000954] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 12.8] [Reference Citation Analysis]
137 Mocroft A, Lundgren JD, Rockstroh JK, Aho I, Wandeler G, Nielsen L, Edwards S, Viard JP, Lacombe K, Fätkenheuer G, Guaraldi G, Laguno M, Llibre J, Elinav H, Flamholc L, Gisinger M, Paduta D, Khromova I, Jilich D, Rozplochowski B, Oprea C, Peters L; EuroSIDA study . Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infect Dis 2020;7:ofaa470. [PMID: 33409325 DOI: 10.1093/ofid/ofaa470] [Reference Citation Analysis]
138 Wang EA, Redmond N, Dennison Himmelfarb CR, Pettit B, Stern M, Chen J, Shero S, Iturriaga E, Sorlie P, Diez Roux AV. Cardiovascular Disease in Incarcerated Populations. J Am Coll Cardiol 2017;69:2967-76. [PMID: 28619198 DOI: 10.1016/j.jacc.2017.04.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
139 Kuo SH, Hung WT, Tang PL, Huang WC, Yang JS, Lin HC, Mar GY, Chang HT, Liu CP. Impact of hepatitis C virus infection on long-term mortality after acute myocardial infarction: a nationwide population-based, propensity-matched cohort study in Taiwan. BMJ Open 2018;8:e017412. [PMID: 29374659 DOI: 10.1136/bmjopen-2017-017412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Poliwczak AR, Białkowska J, Woźny J, Koziróg M, Bała A, Jabłkowski M. Cardiovascular risk assessment by electrocardiographic Holter monitoring in patients with chronic hepatitis C. Arch Med Sci 2020;16:1031-9. [PMID: 32863991 DOI: 10.5114/aoms.2020.96600] [Reference Citation Analysis]
141 Pothineni NV, Rochlani Y, Vallurupalli S, Kovelamudi S, Ahmed Z, Hakeem A, Mehta JL. Comparison of Angiographic Burden of Coronary Artery Disease in Patients With Versus Without Hepatitis C Infection. The American Journal of Cardiology 2015;116:1041-4. [DOI: 10.1016/j.amjcard.2015.06.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
142 Tsai M, Hsu Y, Yu P, Lin C, Kao C. Long-term risk of acute coronary syndrome in hepatitis C virus infected patients without antiviral treatment: A cohort study from an endemic area. International Journal of Cardiology 2015;181:27-9. [DOI: 10.1016/j.ijcard.2014.11.200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
143 Polanka BM, Kundu S, So-Armah KA, Freiberg MS, Gupta SK, Zapolski TCB, Hirsh AT, Bedimo RJ, Budoff MJ, Butt AA, Chang CH, Gottlieb SS, Marconi VC, Womack JA, Stewart JC. Insomnia symptoms and biomarkers of monocyte activation, systemic inflammation, and coagulation in HIV: Veterans Aging Cohort Study. PLoS One 2021;16:e0246073. [PMID: 33561176 DOI: 10.1371/journal.pone.0246073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Kakinami L, Block RC, Adams MJ, Cohn SE, Maliakkal B, Fisher SG. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int J Clin Pract 2013;67:6-13. [PMID: 23241046 DOI: 10.1111/j.1742-1241.2012.02953.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
145 Butt AA, Yan P, Shuaib A, Abou-Samra AB, Shaikh OS, Freiberg MS. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Gastroenterology 2019; 156: 987-996. e8. [PMID: 30445009 DOI: 10.1053/j.gastro.2018.11.022] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 18.0] [Reference Citation Analysis]
146 Zubkin ML, Chervinko VI, Ovchinnikov YV, Kryukov EV, Kotenko ON. [Chronic HCV infection: An internist's opinion (Part 2)]. Ter Arkh 2016;88:138-48. [PMID: 28635834 DOI: 10.17116/terarkh20168811138-148] [Reference Citation Analysis]
147 Olubamwo O, Aregbesola A, Miettola J, Kauhanen J, Tuomainen T. Hepatitis C and risk of coronary atherosclerosis – A systematic review. Public Health 2016;138:12-25. [DOI: 10.1016/j.puhe.2016.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
148 Barakat AAE, Nasr FM, Metwaly AA, Morsy S, Eldamarawy M. Atherosclerosis in chronic hepatitis C virus patients with and without liver cirrhosis. Egypt Heart J. 2017;69:139-147. [PMID: 29622968 DOI: 10.1016/j.ehj.2016.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. Clin Physiol Funct Imaging. 2015;Epub ahead of print. [PMID: 25620553 DOI: 10.1111/cpf.12229] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
150 Nelson KE. The Impact of Chronic Hepatitis C Virus Infection on Mortality. Journal of Infectious Diseases 2012;206:461-3. [DOI: 10.1093/infdis/jis394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
151 Wong RJ, Kanwal F, Younossi ZM, Ahmed A. Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci. 2014;59:1586-1593. [PMID: 24894512 DOI: 10.1007/s10620-014-3222-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
152 Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in Virus Infections. J Clin Med 2021;10:877. [PMID: 33672766 DOI: 10.3390/jcm10040877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
153 Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, Gibert CL, Oursler KK, Rodriguez-Barradas MC, Lim J, Kazis LE, Gottlieb S, Justice AC, Freiberg MS. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med 2011;171:737-43. [PMID: 21518940 DOI: 10.1001/archinternmed.2011.151] [Cited by in Crossref: 46] [Cited by in F6Publishing: 91] [Article Influence: 4.6] [Reference Citation Analysis]
154 Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150:145-155.e4; quiz e15-16. [PMID: 26386298 DOI: 10.1053/j.gastro.2015.09.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 22.8] [Reference Citation Analysis]
155 Maniar A, Ellis C, Asmuth D, Pollard R, Rutledge J. HIV infection and atherosclerosis: evaluating the drivers of inflammation. Eur J Prev Cardiolog 2013;20:720-8. [DOI: 10.1177/2047487312447843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
156 Roed T, Kristoffersen US, Knudsen A, Wiinberg N, Lebech AM, Almdal T, Thomsen RW, Kjær A, Weis N. Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C--a cross-sectional study. Vasc Health Risk Manag 2014;10:55-62. [PMID: 24482574 DOI: 10.2147/VHRM.S53557] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
157 Fernández-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47-52. [PMID: 26390144 DOI: 10.1111/jvh.12447] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
158 Kuniholm MH, Xie X, Anastos K, Kaplan RC, Xue X, Kovacs A, Peters MG, Seaberg EC, French AL, Young MA, Augenbraun M, Martinson JA, Bush KA, Landay AL, Strickler HD. Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women. J Acquir Immune Defic Syndr 2014;67:295-303. [PMID: 25314250 DOI: 10.1097/QAI.0000000000000310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
159 Miyazaki T, Honda A, Ikegami T, Saitoh Y, Hirayama T, Hara T, Doy M, Matsuzaki Y. Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. Hepatol Res. 2011;41:530-541. [PMID: 21501354 DOI: 10.1111/j.1872-034x.2011.00803.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
160 Amador-Cañizares Y, Dueñas-Carrera S. Early interferon-based treatment after detection of persistent hepatitis C virus infection: a critical decision. J Interferon Cytokine Res 2010;30:817-24. [PMID: 20836713 DOI: 10.1089/jir.2010.0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
161 So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS 2014;9:346-54. [PMID: 24824885 DOI: 10.1097/COH.0000000000000065] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
162 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
163 Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496-502. [PMID: 22385985 DOI: 10.1016/j.atherosclerosis.2012.01.051] [Cited by in Crossref: 116] [Cited by in F6Publishing: 115] [Article Influence: 12.9] [Reference Citation Analysis]
164 Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB; ERCHIVES study team. Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis 2015;15:510. [PMID: 26558512 DOI: 10.1186/s12879-015-1268-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
165 Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, Chung RT, Rogal SS;  ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology. 2015;62:365-374. [PMID: 25847403 DOI: 10.1002/hep.27835] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
166 Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med 2021;112:188-200. [PMID: 33205641 DOI: 10.23736/S0026-4806.20.07129-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14. [PMID: 26862398 DOI: 10.1177/2049936115585942] [Cited by in Crossref: 62] [Cited by in F6Publishing: 75] [Article Influence: 12.4] [Reference Citation Analysis]
168 Kutikhin A, Brusina E, Yuzhalin AE. Hepatitis Viruses, Atherosclerosis, and Related Diseases. Viruses and Atherosclerosis. New York: Springer; 2013. pp. 49-63. [DOI: 10.1007/978-1-4614-8863-7_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Kohli P, Ganz P, Ma Y, Scherzer R, Hur S, Weigel B, Grunfeld C, Deeks S, Wasserman S, Scott R, Hsue PY. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". J Am Heart Assoc 2016;5:e002683. [PMID: 27130349 DOI: 10.1161/JAHA.115.002683] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 5.6] [Reference Citation Analysis]
171 Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647-652. [PMID: 23384408 DOI: 10.1111/apt.12234] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 12.6] [Reference Citation Analysis]
172 Maggi P, Bruno G, Perilli F, Saracino A, Volpe A, Santoro C, Ladisa N, Angarano G. Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. In Vivo 2017;31:125-31. [PMID: 28064231 DOI: 10.21873/invivo.11035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
173 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). PLoS One 2018;13:e0208839. [PMID: 30540839 DOI: 10.1371/journal.pone.0208839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
174 Wu A, Burrowes S, Zisman E, Brown TT, Bagchi S. Association of hepatitis C infection and acute coronary syndrome: A case-control study. Medicine (Baltimore) 2021;100:e26033. [PMID: 34032724 DOI: 10.1097/MD.0000000000026033] [Reference Citation Analysis]
175 Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, Di Pietro M, Pan A, Torti C; Italian MASTER Cohort. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PLoS One 2015;10:e0124741. [PMID: 26020949 DOI: 10.1371/journal.pone.0124741] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
176 Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014;61:S69-78. [DOI: 10.1016/j.jhep.2014.08.003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 13.6] [Reference Citation Analysis]